A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians)
JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)
DOI: 10.1093/jacamr/dlag127 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 03.07.2026. Verfasst von Andrea Rabbione und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Regional Center for Infectious Diseases (CEREMI), Lombardy Region…. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NextGenerationEU, MUR.
Abstract (Originalsprache)
Background
Dalbavancin is increasingly used off-label for chronic Gram-positive bone and joint infections (BJIs) requiring prolonged antimicrobial therapy, but optimal dosing strategies and the role of therapeutic drug monitoring (TDM) remain unclear. We evaluated the real-world implementation of a proactive TDM-guided dalbavancin workflow within an outpatient parenteral antimicrobial therapy (OPAT) programme.
Methods
Single-centre prospective observational implementation study including adult patients with BJIs consecutively treated with dalbavancin in OPAT service between July 2022 and August 2025. A multidisciplinary team developed a workflow incorporating TDM-guided pharmacokinetic modelling to individualize dosing intervals after fixed initial administrations (Days 1, 8 and 43). Target Cmin concentrations were ≥8 mg/L, later increased to ≥15 mg/L after European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint revision. Primary outcomes included implementation metrics (feasibility, fidelity and appropriateness). Secondary outcomes were clinical effectiveness, safety and overall workflow success.
Results
The workflow was applied to 101 patients accounting for 418 TDM-guided dalbavancin administrations (feasibility). Three patient-driven treatment discontinuations were observed (3/101, 3.0%), and scheduled administrations occurred within the predefined time window in 335/418 (83.5%) of cases (fidelity). Pharmacological target attainment was achieved in 285/342 (89.6%) of administrations without dosing delays (appropriateness). Clinical effectiveness was achieved in 55/73 (75.3%) patients completing therapy, with 28/101 (28%) still on treatment. Adverse events–related discontinuation occurred in 3/101 (3%) patients. Overall workflow success was observed in 74/101 (73.2%) patients.
Conclusions
A multidisciplinary TDM-guided dalbavancin workflow within an OPAT programme was feasible and safe, achieving high target attainment and favourable clinical outcomes. This approach supports individualized long-acting dalbavancin therapy for complex chronic BJIs.
Autor:innen und Institutionen
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Regional Center for Infectious Diseases (CEREMI), Lombardy Region, Milan, Italy.
- Unit of Clinical Pathology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
- Division of Public Health, Department of Medicine, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
ORCID-Profile: Maria Vittoria Cossu, Gina A Suh, Andrea Gori
Förderung
- NextGenerationEU
- MUR
Zitieren
APA
Rabbione, A., Petri, F., Civati, A., Mariani, C., Landonio, S., Scandiffio, L., Giorgi, R., Foschi, A., Offer, M., Cossu, M. V., Tande, A. J., Cattaneo, D., Dolci, A., Suh, G. A., Gori, A., & Passerini, M. (2026). A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians). JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag127
Vancouver
Rabbione A, Petri F, Civati A, Mariani C, Landonio S, Scandiffio L, et al. A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians). JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag127
BibTeX
@article{Rabbione2026,
author = {Rabbione, Andrea and Petri, Francesco and Civati, Aurora and Mariani, Chiara and Landonio, Simona and Scandiffio, Letizia and Giorgi, Riccardo and Foschi, Antonella and Offer, Martina and Cossu, Maria Vittoria and Tande, Aaron J and Cattaneo, Dario and Dolci, Alberto and Suh, Gina A and Gori, Andrea and Passerini, Matteo},
title = {A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians)},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/jacamr/dlag127}
}
EUVIMED